Turkish Version of the UCLA Prostate Cancer Index

NCT07448545 | Completed

• 1 other identifier: 2021/14-42
• Study Type: observational
• Target: 115
• Locations: 1 country
• Sites: 1

Brief Summary

This study will evaluate the cross-cultural adaptation, validity, and reliability of the Turkish version of the UCLA Prostate Cancer Index in men diagnosed with prostate cancer. The original instrument will be translated and culturally adapted following standardized procedures. The psychometric properties of the Turkish version will be examined in patients attending routine follow-up visits at a urology clinic. Internal consistency will be assessed using Cronbach's alpha coefficients, and test-retest reliability will be evaluated using intraclass correlation coefficients (ICC) in a subset of participants. Measurement error will be determined by calculating the standard error of measurement (SEM) and the smallest real difference at the 95% confidence level (SRD95). Construct validity will be examined through exploratory factor analysis, and convergent validity will be assessed by testing predefined hypotheses regarding correlations between the UCLA Prostate Cancer Index and established quality-of-life instruments (SF-36 and EORTC QLQ-PR25). The findings are expected to provide a reliable and valid prostate cancer-specific quality-of-life assessment tool for use in Turkish-speaking populations.

Conditions

Prostate Cancer (Diagnosis); Quality of Life; Reliability; Validity; UCLA Prostate Cancer Index

Outcome Measures

Primary Outcomes (3)

• UCLA Prostate Cancer Index

  The University of California, Los Angeles (UCLA) Prostate Cancer Index was developed in English in 1998 by Litwin et al. and has been psychometrically validated in prostate cancer populations. It evaluates urinary, sexual, and bowel function and the associated symptom-related bother in men treated for prostate cancer

  1 hour

• EORTC QLQ-PR25

  The EORTC QLQ-PR25 is a prostate cancer-specific module consisting of 25 items and comprising six symptom subdomains: urinary symptoms, incontinence aid, bowel symptoms, hormonal treatment-related symptoms, sexual activity, and sexual functioning

  1 hour

• SF-36

  It is a widely used 36-item questionnaire that evaluates health-related QoL across eight domains, including physical functioning, role limitations due to physical and emotional problems, mental health, vitality, social functioning, bodily pain, and general health

  1 hour

Study Arms (1)

Prostate Cancer Patients

This cohort will consist of men aged 45 years and older who have been diagnosed with prostate cancer and are attending routine follow-up visits at a urology outpatient clinic

Other: Questionnaires

Interventions

Questionnaires OTHER

Participants will complete the Turkish version of the UCLA Prostate Cancer Index along with the SF-36 and EORTC QLQ-PR25 questionnaires. No intervention will be applied.

Prostate Cancer Patients

Eligibility Criteria

• Gender Eligibility Details: This study includes participants who self-identify as male, as prostate cancer is a disease affecting individuals with male reproductive anatomy.
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population consists of men aged 45 years and older who have been diagnosed with prostate cancer and are attending routine follow-up visits at a urology outpatient clinic in Türkiye.

You may qualify if:

• Male patients
• Diagnosis of prostate cancer

You may not qualify if:

• Severe psychiatric or mental disorders that may impair the ability to complete the questionnaires properly
• Presence of congenital deformities

Sponsors & Collaborators

• Lokman Hekim University: lead

Study Sites (1)

Lokman Hekim University, Ankara, Ankara

Ankara, 6510, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Prostatic Neoplasms; Disease

Interventions

Surveys and Questionnaires

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Target Duration: 115 Days
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant profesor

Study Record Dates

• First Submitted: February 26, 2026
• First Posted: March 4, 2026
• Study Start: January 20, 2022
• Primary Completion: January 28, 2026
• Study Completion: January 28, 2026
• Last Updated: March 5, 2026

Record last verified: 2026-02

Locations

TU (1)